Los Angeles Capital Management LLC Decreases Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Los Angeles Capital Management LLC decreased its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 12.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 334,669 shares of the biotechnology company’s stock after selling 46,104 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.56% of Aldeyra Therapeutics worth $1,108,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Laidlaw Wealth Management LLC lifted its stake in Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 4,150 shares during the last quarter. Rhumbline Advisers lifted its stake in Aldeyra Therapeutics by 20.1% during the second quarter. Rhumbline Advisers now owns 76,981 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 12,907 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in Aldeyra Therapeutics during the second quarter worth approximately $200,000. Bank of New York Mellon Corp increased its position in Aldeyra Therapeutics by 21.7% during the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock worth $648,000 after buying an additional 34,885 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in Aldeyra Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock worth $292,000 after buying an additional 6,944 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. StockNews.com lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Aldeyra Therapeutics Price Performance

Shares of ALDX stock opened at $6.19 on Thursday. The business’s fifty day moving average price is $4.53 and its 200 day moving average price is $4.01. Aldeyra Therapeutics, Inc has a 1-year low of $1.42 and a 1-year high of $7.42. The firm has a market capitalization of $367.77 million, a PE ratio of -12.14 and a beta of 1.45.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.